

From: [Okuzumi-Tatsuya\(奥住 竜哉\)](#)
To: michael.szardenings@izi.fraunhofer.de
Subject: [PepTalk] Fraunhofer - Ajinomoto - Site-specific conjugation for ADC - Thank you
Date: Saturday, February 9, 2019 4:30:46 AM
Attachments: [2019-01-16 PepTalk 2019 AJINOMOTO Luncheon Presentation.pdf](#)
[image001.png](#)
[image003.png](#)

Dear Michel Szardings,

It was great meeting you in PepTalk. Thank you very much for your interest in our ADC conjugation technology AJICAP™.

It would be great if you circulate the information to whom may have an interest on conjugation technology in your institute.

Advantage of AJICAP™ is as follows:

1. Straightforward CMC
 - Direct modification of intact antibody
 - No genetic modification required
2. Enhancement of Therapeutic Window compared to stochastic ADCs
 - Site specific, controlled DAR 2
3. Wide drug-linker compatibility: reactive group compatibility includes thiol, alkyne, azide, etc
4. High yields, short conjugation reaction times, ease to manufacture

We have already developed 2nd generation AJICAP™ which has:

- More streamlined reaction sequence
- No red/ox reaction
- Less aggregation - below 1%.

We could introduce the detail of AJICAP™ via TC or email upon your request. Please feel free to ask questions if something is unclear. We are happy to answer.

Best regards,

TATSUYA OKUZUMI, Ph.D.

Associate General Manager - R&D planning Dept.

P: +81.70.4360.7840 | 1-15-1, Kyobashi, Chuo-ku, Tokyo 104-8315, JAPAN

AJINOMOTO CO., INC. | www.ajinomoto.com

Exhibit 1019
AJINOMOTO CO., INC.
IPR2025-00283

From: [Szardenings, Michael](#)
To: [Okuzumi-Tatsuya\(奥住 竜哉\)](#)
Subject: AW: [PepTalk] Fraunhofer - Ajinomoto - Site-specific conjugation for ADC - Thank you
Date: Sunday, February 10, 2019 1:07:58 PM
Attachments: [image001.png](#)
[image002.png](#)

Dear all

ありがとうThank you very much for coming back! I had a few hard weeks back in the office, so I have been condemned to work some issues first. I like your technology, because of its ease. Do you have more information available?

From my part I have little problems understanding the technology. But I am one of only a very few chemists in a "biological" "medical" environment.

The technology could be very helpful for us, because:

- We have peptides with high specificities for either tumors or their surroundings. Several of them have been tested in tumor models in mice. Your technology would allow a quick evaluation, whether they (at least in this setting) would also allow an enrichment of antibodies in the tumor tissue.
- Have you ever thought about attaching the peptide to cells presenting antibodies like CAR-T-cells? What are actually the reaction times? Our institute is

Another question: Is Ajinomoto interested in food allergies, both food analysis and completely novel allergy diagnostics based on epitopes allowing firstly a really precise diagnosis? I do not dare to attach the long presentation, but you can easily download it at <https://www.izi.fraunhofer.de/en/departments/leipzig-location/immunology/ligand-development.html>. There is a long chapter about epitope fingerprinting in patient sera. We also map antibody epitopes as a routine service, see our spin off www.epitopic.com

So, yes, I am definitely interested in entering more talks and discussions!

Regards
Michael

Dr. Michael Szardenings
Ligand Development Unit
Fraunhofer Institute for Cell Therapy and Immunology
Perlickstr. 1, 04103 Leipzig, Germany
Tel: 0049-341-35536 2805
Cell: 0049 159 044 268 49
Fax: 0049-341-35536 82805
michael.szardenings@izi.fraunhofer.de
www.izi.fraunhofer.de

Von: Okuzumi-Tatsuya(奥住 竜哉) [mailto:tatsuya_okuzumi@ajinomoto.com]
Gesendet: Samstag, 9. Februar 2019 10:31
An: Szardenings, Michael
Betreff: [PepTalk] Fraunhofer - Ajinomoto - Site-specific conjugation for ADC - Thank you

Dear Michel Szardings,

It was great meeting you in PepTalk. Thank you very much for your interest in our ADC conjugation technology AJICAP™.

It would be great if you circulate the information to whom may have an interest on conjugation technology in your institute.

Advantage of AJICAP™ is as follows:

1. Straightforward CMC
 - Direct modification of intact antibody
 - No genetic modification required
2. Enhancement of Therapeutic Window compared to stochastic ADCs
 - Site specific, controlled DAR 2
3. Wide drug-linker compatibility: reactive group compatibility includes thiol, alkyne, azide, etc
4. High yields, short conjugation reaction times, ease to manufacture

We have already developed 2nd generation AJICAP™ which has:

- More streamlined reaction sequence
- No red/ox reaction
- Less aggregation - below 1%.

We could introduce the detail of AJICAP™ via TC or email upon your request. Please feel free to ask questions if something is unclear. We are happy to answer.

Best regards,

TATSUYA OKUZUMI, Ph.D.

Associate General Manager - R&D planning Dept.

P: +81.70.4360.7840 | 1-15-1, Kyobashi, Chuo-ku, Tokyo 104-8315, JAPAN

AJINOMOTO CO., INC. | www.ajinomoto.com